Immunotherapy shows promise as First-Line attack on tough lung cancer

NCT ID NCT03003962

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a drug called durvalumab (an immunotherapy that helps the immune system fight cancer) to standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, no specific gene mutations, and good physical health took part. The main goal was to see if durvalumab helps people live longer than chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CARCINOMA NSCLC

Contacts and locations

Locations

Research Site

Anaheim, California, 92801, United States
Research Site

Box Hill, 3128, Australia
Research Site

Gosford, 2250, Australia
Research Site

Kogarah, 2217, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Beijing, 100032, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100853, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130000, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Guangzhou, 510080, China
Research Site

Guangzhou, 510095, China
Research Site

Haikou, 570311, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310022, China
Research Site

Jinan, 250031, China
Research Site

Linhai, 317000, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210009, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200030, China
Research Site

Shenyang, 110042, China
Research Site

Shijiazhuang, 050020, China
Research Site

Ürümqi, 830000, China
Research Site

Ürümqi, 830054, China
Research Site

Wanzhou, 404000, China
Research Site

Wenzhou, CN-325000, China
Research Site

Wuhan, 430010, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Xi'an, 710038, China
Research Site

Xi'an, 710061, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhuhai, 519099, China
Research Site

Budapest, 1083, Hungary
Research Site

Budapest, 1121, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Deszk, 6772, Hungary
Research Site

Farkasgyepü, 8582, Hungary
Research Site

Gyöngyös - Mátraháza, 3200, Hungary
Research Site

Székesfehérvár, 8000, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Almelo, 7600SZ, Netherlands
Research Site

Bialystok, 15-027, Poland
Research Site

Grudziądz, 86-300, Poland
Research Site

Koszalin, 75-581, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Mrozy, 05-320, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Wroclaw, 53-413, Poland
Research Site

Arkhangelsk, 163045, Russia
Research Site

Moscow, 115478, Russia
Research Site

Novosibirsk, 630108, Russia
Research Site

Omsk, 644013, Russia
Research Site

Rostov-on-Don, 344037, Russia
Research Site

Saint Petersburg, 194291, Russia
Research Site

Saint Petersburg, 196603, Russia
Research Site

Saint Petersburg, 197183, Russia
Research Site

Saint Petersburg, 197342, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Volgograd, 400138, Russia
Research Site

Changwon-si, 51353, South Korea
Research Site

Cheongju-si, 28644, South Korea
Research Site

Daegu, 42415, South Korea
Research Site

Incheon, 21565, South Korea
Research Site

Jinju, 660-702, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Taichung, 402, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Muang, 50200, Thailand
Research Site

Songkhla, 90110, Thailand
Research Site

Ankara, 06490, Turkey (Türkiye)
Research Site

Istanbul, 34030, Turkey (Türkiye)
Research Site

Istanbul, 34854, Turkey (Türkiye)
Research Site

Malatya, 44100, Turkey (Türkiye)
Research Site

Pamukkale, 20070, Turkey (Türkiye)
Research Site

Can Tho, 900000, Vietnam
Research Site

Hanoi, 100000, Vietnam
Research Site

Hanoi, 10000, Vietnam
Research Site

Ho Chi Minh City, 10000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.